OncoMed Pharmaceuticals, Inc. and Fluidigm Corporation today announced a new initiative to apply Fluidigm's unique microfluidic tools to the analysis of tumor cell heterogeneity, including cancer stem cells. The collaboration will combine Fluidigm's advanced microfluidic platforms with OncoMed's proprietary cancer stem cell sorting technology to generate unique tools for analyzing, quantifying and developing treatments directed at a highly tumorigenic cell population.
In the initial application, OncoMed will apply Fluidigm's BioMark(TM) System along with Fluidigm's proprietary Dynamic Array(TM) integrated fluidic circuits (IFCs) to perform detailed gene expression analysis of solid tumors at the whole tumor and single-cell level. This phase will track changes in cancer stem cells found in human tumors following treatment with OncoMed's extensive pipeline of therapeutic monoclonal antibodies. The companies will apply this same technology to analyze tumor heterogeneity and cancer stem cell frequency across OncoMed's proprietary human tumor bank which includes approximately one hundred human tumor biopsies that have been engrafted and minimally passaged in immunocompromised mice. The OncoMed/Fluidigm collaboration also has the potential to include novel and next-generation microfluidic and tissue sample-preparation technologies that Fluidigm is currently developing.
"We are excited to be working with Fluidigm, a world leader in microfluidic technology, to enable the single-cell analysis of cancer stem cells as a tool for identifying unique drug targets. This technology has broad applications, including the ability to assess the safety and efficacy of therapeutic antibodies that have been generated to eradicate these important cells which fuel the growth and proliferation of solid tumors," said Paul Hastings, OncoMed's President and Chief Executive Officer.
"This will be a highly productive alliance. The combination of OncoMed's expertise in cancer and cancer stem cells, together with Fluidigm's unique single-cell analysis technology should yield important new therapeutic discoveries," said Gajus Worthington, President and Chief Executive Officer of Fluidigm. "Our respective capabilities are highly complementary."
Do neighborhood-level disparities in breast cancer–specific survival remain after accounting for individual, tumor, and treatment characteristics?